Bio-Rad Laboratories, Inc.
$302.22
▼
-1.27%
2026-04-22 10:12:13
www.bio-rad.com
NYQ: BIO
Explore Bio-Rad Laboratories, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$8.04 B
Current Price
$302.22
52W High / Low
$343.12 / $211.43
Stock P/E
10.88
Book Value
$276.16
Dividend Yield
—
ROCE
2.17%
ROE
10.84%
Face Value
—
EPS
$27.85
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
7,450
Beta
1.16
Debt / Equity
18.58
Current Ratio
5.62
Quick Ratio
4.19
Forward P/E
24.61
Price / Sales
2.92
Enterprise Value
$7.38 B
EV / EBITDA
17.1
EV / Revenue
2.86
Rating
Hold
Target Price
$302.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Inspire Medical Systems, Inc. | $56.97 | 11.28 | $1.64 B | — | 6.28% | 19.77% | $163.35 / $48.3 | $27.33 |
| 2. | LivaNova PLC | $65.81 | — | $3.6 B | — | 11.09% | -19.24% | $71.92 / $34 | $21.96 |
| 3. | SI-BONE, Inc. | $14.32 | — | $632.45 M | — | -10.47% | -10.97% | $21.89 / $12.15 | $4.07 |
| 4. | Pacific Biosciences of California, Inc. | $1.74 | — | $510.38 M | — | -78.39% | -2.13% | $2.73 / $0.85 | $0.02 |
| 5. | Haemonetics Corporation | $61.17 | 16.14 | $2.83 B | — | 10.74% | 19.3% | $87.32 / $47.31 | $19.46 |
| 6. | 20/20 Biolabs, Inc. | $1.71 | — | — | — | -253.94% | -5.03% | $50 / $1.51 | $0.01 |
| 7. | DexCom, Inc. | $63.4 | 30.77 | $24.57 B | — | 21.72% | 34.5% | $89.98 / $54.11 | $7.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 693.2 M | 653 M | 651.6 M | 585.4 M | 667.48 M | — |
| Operating Profit | 53.9 M | 63.9 M | 77.1 M | 23.7 M | 58.33 M | — |
| Net Profit | 720 M | -341.9 M | 317.8 M | 64 M | -715.8 M | — |
| EPS in Rs | 32.84 | -15.59 | 14.5 | 2.92 | -32.65 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.58 B | 2.57 B | 2.67 B | 2.8 B |
| Operating Profit | 218.6 M | 269 M | 337.8 M | 475.1 M |
| Net Profit | 759.9 M | -1.84 B | -637.3 M | -3.63 B |
| EPS in Rs | 34.66 | -84.12 | -29.07 | -165.45 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 10.58 B | 9.36 B | 12.3 B | 13.5 B |
| Total Liabilities | 3.12 B | 2.79 B | 3.56 B | 3.89 B |
| Equity | 7.45 B | 6.57 B | 8.74 B | 9.62 B |
| Current Assets | 2.91 B | 3.03 B | 3.05 B | 3.16 B |
| Current Liabilities | 517 M | 467.8 M | 522.8 M | 568.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 532.2 M | 455.2 M | 374.9 M | 194.4 M |
| Investing CF | -189.7 M | -160.2 M | 20.2 M | -1.21 B |
| Financing CF | -283.2 M | -218.8 M | -425.6 M | 973.6 M |
| Free CF | 374.6 M | 266.2 M | 218.2 M | 80.1 M |
| Capex | -157.6 M | -189 M | -156.7 M | -114.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -3.92% | -4.67% | — | — |
| Earnings Growth % | -189.38% | 82.43% | — | — |
| Profit Margin % | -71.86% | -23.86% | -129.45% | — |
| Operating Margin % | 10.48% | 12.65% | 16.95% | — |
| Gross Margin % | 53.73% | 53.42% | 55.93% | — |
| EBITDA Margin % | -83.46% | -24.51% | -161.62% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.